Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1183-1193

  Bousquet, Guilhem ^a,b,c   Varna, Mariana ^a,b   Ferreira, Irmine ^a,b   Wang, Li ^a,b,e   Mongiat Artus, Pierre ^c   Leboeuf, Christophe ^a,b   De Bazelaire, Cédric ^a,b,c   Faivre, Sandrine ^a,b   Bertheau, Philippe ^a,b,c   Raymond, Eric ^a,b   Germain, Stéphane ^c,d   Janin, Anne ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Paris Sciences et Lettres   (France)

^e Shanghai Instituted of Technology   (China)

Author keywords

Endothelial cell; Murine model; Sunitinib; Tumor cell death; Xenograft

Indexed keywords

CD135 ANTIGEN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MICROVASCULATURE; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; TREATMENT DURATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PYRROLES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890334338     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2300-0     Document Type: Article

References (36)

1. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32. doi: 10.1186/1479-5876-5-32
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390. doi: 10.1056/NEJMoa0708857
3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676. doi: 10.1056/NEJMoa072113
4. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773. doi: 10.1093/jnci/djr128
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590. doi: 10.1200/JCO.2008.20.1293
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124. doi: 10.1056/NEJMoa065044
7. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131. doi: 10.1007/s10549-010-0788-0
8. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794-800. doi: 10.1016/S1470-2045(09)70171-8
9. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovacs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G (2010) Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15:285-292. doi: 10.1634/theoncologist.2009-0316
10. Jonasch E, Futreal A, Davis I, Bailey S, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita A, Rini BI, Sharma P, Atkins M, Walker C, Rathmell WK (2012) State-of-the-science: an update on renal cell carcinoma. Mol Cancer Res. doi: 10.1158/1541-7786.MCR-12-0117
11. Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S (2011) Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 9:120. doi: 10.1186/1479-5876-9-120
12. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK (2011) Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res 17:918-927. doi: 10.1158/1078-0432.CCR-10-0515
13. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naimi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S (2010) Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 5:e10715. doi: 10.1371/journal.pone.0010715
14. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14:435-446. doi: 10.1016/j.ccr.2008.10.016
15. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S (2008) Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270:229-233. doi: 10.1016/j.canlet.2008.05.007
16. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423. doi: 10.1215/15228517-2007-024
17. Tanaka Y, Shibata MA, Morimoto J, Otsuki Y (2011) Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Anticancer Res 31:1225-1234
18. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
19. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053-1062. doi: 10.1158/0008-5472.CAN-09-3722
20. Zhou Q, Guo P, Gallo JM (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14:1540-1549. doi: 10.1158/1078-0432.CCR-07-4544
21. Maluf FC, Fernandes Gdos S, Kann AG, Aguilar-Ponce JL, de la Garza J, Buzaid AC (2008) Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treat Rev 34:750-760. doi: 10.1016/j.ctrv.2008.07.002
22. Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de The H, Bertheau P (2009) p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 124:991-997. doi: 10.1002/ijc.24049
23. Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, Meignin V, Oksenhendler E, Maignin CL, Calvo F, Briere J, Gisselbrecht C, Janin A (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 84:1512-1519. doi: 10.1038/labinvest.3700145
24. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16:3-11. doi: 10.1038/cdd.2008.150
25. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35. doi: 10.1200/JCO.2005.02.2194
26. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748. doi: 10.1200/JCO.2007.15.5416
27. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, Haubitz M (2010) Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 10:695. doi: 10.1186/1471-2407-10-695
28. Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B (2011) Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 104:1144-1150. doi: 10.1038/bjc.2011.72
29. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69:2506-2513. doi: 10.1158/0008-5472.CAN-08-4323
30. Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR (2011) Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 13:49-59
31. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591. doi: 10.1038/nrc2403
32. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049. doi: 10.1056/NEJMra0706596
33. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC (2011) VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 6:e25668. doi: 10.1371/journal.pone.0025668
34. Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y (2012) 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett 3:1195-1202. doi: 10.3892/ol.2012.662
35. Garcia-Donas J, Leandro-Garcia LJ, Gonzalez Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodriguez-Antona C (2013) Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. doi: 10.1093/annonc/mdt219
36. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15:4838-4846. doi: 10.1158/1078-0432.CCR-08-2780